Copyright Reports & Markets. All rights reserved.

Global JE Inactivated Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global JE Inactivated Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Hamster Kidney Cells
    • 1.3.3 Vero Cells
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global JE Inactivated Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Clinic
  • 1.5 Global JE Inactivated Vaccine Market Size & Forecast
    • 1.5.1 Global JE Inactivated Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global JE Inactivated Vaccine Sales Quantity (2021-2032)
    • 1.5.3 Global JE Inactivated Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Bharat Biotech
    • 2.1.1 Bharat Biotech Details
    • 2.1.2 Bharat Biotech Major Business
    • 2.1.3 Bharat Biotech JE Inactivated Vaccine Product and Services
    • 2.1.4 Bharat Biotech JE Inactivated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Bharat Biotech Recent Developments/Updates
  • 2.2 Biological E. Limited
    • 2.2.1 Biological E. Limited Details
    • 2.2.2 Biological E. Limited Major Business
    • 2.2.3 Biological E. Limited JE Inactivated Vaccine Product and Services
    • 2.2.4 Biological E. Limited JE Inactivated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Biological E. Limited Recent Developments/Updates
  • 2.3 Biken
    • 2.3.1 Biken Details
    • 2.3.2 Biken Major Business
    • 2.3.3 Biken JE Inactivated Vaccine Product and Services
    • 2.3.4 Biken JE Inactivated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Biken Recent Developments/Updates
  • 2.4 Seqirus
    • 2.4.1 Seqirus Details
    • 2.4.2 Seqirus Major Business
    • 2.4.3 Seqirus JE Inactivated Vaccine Product and Services
    • 2.4.4 Seqirus JE Inactivated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Seqirus Recent Developments/Updates
  • 2.5 Liaoning Chengda
    • 2.5.1 Liaoning Chengda Details
    • 2.5.2 Liaoning Chengda Major Business
    • 2.5.3 Liaoning Chengda JE Inactivated Vaccine Product and Services
    • 2.5.4 Liaoning Chengda JE Inactivated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Liaoning Chengda Recent Developments/Updates
  • 2.6 Valneva Austria GmbH
    • 2.6.1 Valneva Austria GmbH Details
    • 2.6.2 Valneva Austria GmbH Major Business
    • 2.6.3 Valneva Austria GmbH JE Inactivated Vaccine Product and Services
    • 2.6.4 Valneva Austria GmbH JE Inactivated Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Valneva Austria GmbH Recent Developments/Updates

3 Competitive Environment: JE Inactivated Vaccine by Manufacturer

  • 3.1 Global JE Inactivated Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global JE Inactivated Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global JE Inactivated Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of JE Inactivated Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 JE Inactivated Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 JE Inactivated Vaccine Manufacturer Market Share in 2025
  • 3.5 JE Inactivated Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 JE Inactivated Vaccine Market: Region Footprint
    • 3.5.2 JE Inactivated Vaccine Market: Company Product Type Footprint
    • 3.5.3 JE Inactivated Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global JE Inactivated Vaccine Market Size by Region
    • 4.1.1 Global JE Inactivated Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global JE Inactivated Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global JE Inactivated Vaccine Average Price by Region (2021-2032)
  • 4.2 North America JE Inactivated Vaccine Consumption Value (2021-2032)
  • 4.3 Europe JE Inactivated Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific JE Inactivated Vaccine Consumption Value (2021-2032)
  • 4.5 South America JE Inactivated Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa JE Inactivated Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global JE Inactivated Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global JE Inactivated Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global JE Inactivated Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global JE Inactivated Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global JE Inactivated Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global JE Inactivated Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America JE Inactivated Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America JE Inactivated Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America JE Inactivated Vaccine Market Size by Country
    • 7.3.1 North America JE Inactivated Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America JE Inactivated Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe JE Inactivated Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe JE Inactivated Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe JE Inactivated Vaccine Market Size by Country
    • 8.3.1 Europe JE Inactivated Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe JE Inactivated Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific JE Inactivated Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific JE Inactivated Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific JE Inactivated Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific JE Inactivated Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific JE Inactivated Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America JE Inactivated Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America JE Inactivated Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America JE Inactivated Vaccine Market Size by Country
    • 10.3.1 South America JE Inactivated Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America JE Inactivated Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa JE Inactivated Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa JE Inactivated Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa JE Inactivated Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa JE Inactivated Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa JE Inactivated Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 JE Inactivated Vaccine Market Drivers
  • 12.2 JE Inactivated Vaccine Market Restraints
  • 12.3 JE Inactivated Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of JE Inactivated Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of JE Inactivated Vaccine
  • 13.3 JE Inactivated Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 JE Inactivated Vaccine Typical Distributors
  • 14.3 JE Inactivated Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global JE Inactivated Vaccine market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Inactivated vaccines are safer
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global JE Inactivated Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global JE Inactivated Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global JE Inactivated Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global JE Inactivated Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global JE Inactivated Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for JE Inactivated Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global JE Inactivated Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bharat Biotech, Biological E. Limited, Biken, Seqirus, Liaoning Chengda, Valneva Austria GmbH, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    JE Inactivated Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Hamster Kidney Cells
    Vero Cells
    Market segment by Application
    Hospital
    Clinic
    Major players covered
    Bharat Biotech
    Biological E. Limited
    Biken
    Seqirus
    Liaoning Chengda
    Valneva Austria GmbH
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe JE Inactivated Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of JE Inactivated Vaccine, with price, sales quantity, revenue, and global market share of JE Inactivated Vaccine from 2021 to 2026.
    Chapter 3, the JE Inactivated Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the JE Inactivated Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and JE Inactivated Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of JE Inactivated Vaccine.
    Chapter 14 and 15, to describe JE Inactivated Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now